CN Patent

CN102271673A — 尽管接受包括dpp-iv抑制剂的二甲双胍治疗但血糖控制仍不足的患者中的糖尿病的治疗

Assigned to Boehringer Ingelheim International GmbH · Expires 2011-12-07 · 14y expired

What this patent protects

本发明涉及具体DPP-4抑制剂，其特别适于改善尽管接受二甲双胍治疗但血糖控制仍不足的II型糖尿病患者的血糖控制。

USPTO Abstract

本发明涉及具体DPP-4抑制剂，其特别适于改善尽管接受二甲双胍治疗但血糖控制仍不足的II型糖尿病患者的血糖控制。

Drugs covered by this patent

Patent Metadata

Patent number
CN102271673A
Jurisdiction
CN
Classification
—
Expires
2011-12-07
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.